Treace narrows 2026 revenue outlook to $206M-$210M and sees $700M TAM expansion from new products
FROM THE WIRE · SEEKINGALPHA.COM
Earnings Call Insights: Treace Medical Concepts (TMCI) Q3 2026 MANAGEMENT VIEW * "We're encouraged by our third quarter performance, driven by double-digit case volume growth and continued market share gains" (Founder, Chairman & CEO John Treace). * "We're narrowing our full…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralNarrowed guidance and an expected return to growth in Q4 are relevant for this small-cap medtech stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01CEO John Treace said the third quarter was encouraging, driven by double-digit case volume growth.
- 02The company narrowed its 2026 revenue guidance to a range of $206 million to $210 million.
- 03New 2026 product introductions are expected to expand the total addressable market by about $700 million.
- 04Approximately 45% of Lapiplasty surgeons used at least one of the three new bunion systems through Q3.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets